Clinical trial
Phase II Study of Pembrolizumab and Bevacizumab in Combination With Platinum-based Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Patients With Platinum-sensitive Recurrent Ovarian Cancer
NCT05158062 is registered in ClinicalTrials.gov with Kosei Hasegawa, MD, PhD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Pembrolizumab and Bevacizumab in Combination With Platinum-based Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Patients With Platinum-sensitive Recurrent Ovarian Cancer
- Lead sponsor
- Kosei Hasegawa, MD, PhD
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- April 20, 2022
- Completion date
- November 30, 2024
- Enrollment
- 35 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.